Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (6): 570-577.doi: 10.3969/j.issn.1000-6621.2020.06.007
• Original Articles • Previous Articles Next Articles
HUANG Guo-jun*, GAO Yuan, TANG Xi-liang, GAO Xiao, BAI Li-qiong()
Received:
2019-11-30
Online:
2020-06-10
Published:
2020-06-11
Contact:
BAI Li-qiong
E-mail:liqiong99@126.com
HUANG Guo-jun, GAO Yuan, TANG Xi-liang, GAO Xiao, BAI Li-qiong. Efficacy and safety of thymopentin in adjuvant treatment of retreatment positive pulmonary tuberculosis: a Meta-analysis[J]. Chinese Journal of Antituberculosis, 2020, 42(6): 570-577. doi: 10.3969/j.issn.1000-6621.2020.06.007
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.06.007
纳入 研究 | 年份 | 样本量(例) | 年龄(岁, | 性别(例,男/女) | 常规治疗 方案 | 胸腺五肽用法 | 结局指标 | |||
---|---|---|---|---|---|---|---|---|---|---|
T/C | T/C | T | C | |||||||
文献[ | 2017 | 63/63 | 43.2±3.5/42.4±3.4 | 33/30 | 31/32 | 6H-R-Z-E | 1mg/次, 1次/d,肌内注射,6个月 | ②③④⑤⑥⑦⑧ | ||
文献[ | 2017 | 100/100 | 45.2±5.3/45.2±5.4 | 75/25 | 77/23 | 2H-R-Z-E-S/6H-R-Z-E | 20mg/次,1次/d,静脉滴注,2个月 | ①②⑤ | ||
文献[ | 2019 | 52/52 | 43.8±4.1/43.7±4.2 | 34/18 | 33/19 | 2H-R-Z-E/6H-R-E | 10mg/次,1次/d,静脉滴注,2个月 | ①②③⑥⑦ | ||
文献[ | 2017 | 70/64 | 34.8±5.4/34.3±5.4 | 38/32 | 36/28 | 2H-R-Z-E-S/10H-R-Z-E | 20mg/次,1次/d,静脉滴注,2个月 | ①②⑤ | ||
文献[ | 2013 | 73/67 | 34.9±5.4/34.3±5.4 | 41/32 | 38/29 | 2H-R-Z-E-S/10H-R-Z-E | 20mg/次,1次/d,静脉滴注,2个月 | ①②⑤ | ||
文献[ | 2019 | 34/34 | -/- | 18/16 | 17/17 | 2H-R-Z-E/2H-R | 80mg/d,1次/d,静脉滴注,2个月 | ②③④⑤⑥⑦⑧ | ||
文献[ | 2018 | 45/45 | 41.9±3.9/42.0±4.1 | 24/21 | 23/22 | 3H-R-Z-E/6H-R-E | 80mg/次,1次/d,静脉滴注,2个月 | ②⑥⑦⑧ | ||
文献[ | 2017 | 47/47 | 44.2±4.1/43.9±4.1 | 28/19 | 26/21 | 3H-R-Z-E/6H-R-E | 80mg/次,1次/d,静脉滴注,3个月 | ②③④⑤⑥⑦⑧ | ||
文献[ | 2019 | 37/37 | 51.3±4.9/54.3±5.4 | 23/14 | 22/15 | 6H-R-Z-E | 1mg/次,1次/d,肌内注射,6个月 | ②③④ | ||
文献[ | 2018 | 32/32 | 50.7±4.2/50.6±4.3 | 19/13 | 18/14 | 12H-R-Z-E-S | 1 支/次,1次/2d,肌内注射,12个月 | ② | ||
文献[ | 2012 | 47/45 | -/- | -/- | -/- | 2H-R-Z-E/6H-R-E | 1mg/次,1次/d,静脉滴注或肌内注射, 6个月 | ①②③⑤ | ||
文献[ | 2014 | 75/75 | 37.6±3.7/35.6±4.7 | 39/36 | 45/30 | 2H-R-Z-E-S/10H-R-Z-E | 20mg/次,1次/d,静脉滴注,2个月 | ①② | ||
文献[ | 2019 | 44/44 | 52.3±11.1/50.6±10.9 | 28/16 | 32/12 | 2H-R-Z-E-S/10H-R-Z-E | 1mg/次,1次/2d,皮下注射,6个月 | ②③④⑤ | ||
文献[ | 2018 | 49/48 | 41.5±6.5/39.5±7.5 | 25/24 | 26/22 | 2H-R-Z-E/4H-R | 80mg/次,1次/d,静脉滴注,2个月 | ②③④⑤⑥⑧ | ||
文献[ | 2018 | 41/41 | 42.1±8.4/41.7±8.4 | 21/20 | 23/18 | 6H-R-Z-E | 1ml/次,1次/d,肌内注射,6个月 | ②③ | ||
文献[ | 2017 | 48/48 | 51.3±8.7/50.8±8.8 | 29/19 | 27/21 | 2H-R-Z-E-S/10H-R-Z-E | 20mg/次,1次/d,静脉滴注,2个月 | ② | ||
文献[ | 2016 | 69/69 | -/- | -/- | -/- | 2H-R-Z-E/4H-R | 80mg/次,1次/d,静脉滴注,2个月 | ②③④⑥⑦⑧ | ||
文献[ | 2019 | 25/25 | 42.8±8.1/42.0±7.1 | 14/11 | 18/7 | 2H-R-Z-E/4H-R | 1mg/次,1次/d,静脉滴注,2个月 | ②⑥⑦⑧ |
纳入研究 | 随机方法 | 分配隐藏 | 盲法 | 结果数据完整 | 选择性报告研究结果 | 其他偏倚来源 |
---|---|---|---|---|---|---|
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机数字表法 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 不清楚 | 不清楚 | 不清楚 | 是 | 是 | 是 |
文献[ | 抽签 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 单双号 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机数字表法 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 不清楚 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 双盲 | 是 | 是 | 不清楚 |
文献[ | 随机分组 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
[1] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09. |
[2] | 王玉红, 董雅坤, 王智慧 , 等. 首次复治涂阳肺结核患者耐药情况分析. 中国防痨杂志, 2017,39(2):179-183. |
[3] | 白丽琼, 肖水源, 张贻瑞 , 等. 结核病疾病负担研究进展. 中国防痨杂志, 2013,35(1):77-80. |
[4] | 朱莉贞, 高孟秋, 陈巍 , 等. 复治肺结核化疗新方案与原复治方案的临床对照研究. 中国防痨杂志, 2012,34(5):304-309. |
[5] | 罗萍, 屠德华, 洪峰 , 等. 177例复治肺结核使用标准复治方案的疗效分析. 中国防痨杂志, 2013,35(5):347-351. |
[6] | 陈娜 . 胸腺五肽联合常规化疗对复治菌阳肺结核患者呼吸功能及免疫功能的影响. 现代中西医结合杂志, 2017,26(15):1621-1623, 1643. |
[7] | 程云, 李彦春 . 异烟肼联合胸腺五肽治疗复治菌阳肺结核的疗效观察. 中国医药指南, 2017,15(34):63-64. |
[8] | 党萍 . 胸腺五肽联合抗结核药物治疗复治涂阳肺结核对机体免疫功能的影响. 健康前沿, 2019,28(7):33-34. |
[9] | 郭风云 . 异烟肼联合胸腺五肽治疗复治菌阳肺结核的临床效果探讨. 基层医学论坛, 2017,21(14):1744-1745. |
[10] | 韩文革, 潘兆宝, 王法贞 , 等. 异烟肼联合胸腺五肽治疗复治菌阳肺结核的疗效观察. 中华医院感染学杂志, 2013,23(17):4267-4268, 4271. |
[11] | 姜继军, 张玮 . 复治菌阳肺结核患者应用胸腺五肽治疗的临床疗效. 临床肺科杂志, 2019,24(3):532-534. |
[12] | 兰小华 . 胸腺五肽联合常规抗结核治疗复治菌阳肺结核疗效及对患者免疫功能的影响研究. 当代医学, 2018,24(21):166-168. |
[13] | 李营 . 胸腺五肽联合抗结核药物治疗复治涂阳肺结核对机体免疫功能的影响及疗效观察. 临床肺科杂志, 2017,22(1):32-35. |
[14] | 刘岩 . 胸腺五肽治疗复治菌阳肺结核的临床效果及对患者呼吸功能的影响. 医学信息, 2019,32(8):159-160. |
[15] | 石慧 . 异烟肼联合胸腺五肽治疗复治菌阳肺结核的临床效果探讨. 中国医药指南, 2018,16(3):151-152. |
[16] | 孙凤艳 . 化疗联合胸腺五肽治疗菌阳肺结核的疗效评价. 中国医药指南, 2012,10(3):122-123. |
[17] | 塔桂兰 . 胸腺五肽联合化学药物治疗复治菌阳肺结核的疗效观察. 中国农村卫生, 2014,( 13):57-58. |
[18] | 田起钰, 冯辽辽 . 胸腺五肽联合常规化疗方案治疗复治菌阳性肺结核的效果. 临床医学研究与实践, 2019,4(19):23-24. |
[19] | 王明远 . 胸腺五肽应用于复治菌阳肺结核的效果及对免疫功能与呼吸功能的影响. 首都食品与医药, 2018,25(20):48. |
[20] | 吴连革 . 探讨胸腺五肽联合常规化疗对复治菌阳肺结核的疗效及相关指标的影响. 中国现代药物应用, 2018,12(21):104-105. |
[21] | 张欣鹏 . 联合应用异烟肼和胸腺五肽治疗复治菌阳肺结核的临床观察. 中国医药指南, 2016,14(11):155. |
[22] | 周小妮 . 胸腺五肽联合常规化疗治疗复治菌阳肺结核的疗效及对患者呼吸功能和免疫功能的影响. 海南医学院学报, 2016,22(4):343-345, 349. |
[23] | 周晓均, 林小棠 . 胸腺五肽辅助治疗复治菌阳肺结核的效果及对呼吸功能、免疫功能的影响. 海峡药学, 2019,31(5):197-198. |
[24] | Higgins JPT, Green S . Cochrane handbook for systematic reviews of interventions version 5.1.0. Chichester: John Wiley & Sons, 2011. |
[25] | 杨锐富, 袁殷茹, 张敏 . 胸腺五肽辅助治疗肺结核合并糖尿病疗效与安全性的Meta分析. 广东药科大学学报, 2018,34(5):629-636. |
[26] | 丁毅 . 胸腺五肽对初治肺结核患者免疫功能和痰菌阴转率的影响. 临床肺科杂志, 2013,18(12):2176-2177. |
[27] | 刘士甫, 赵磊, 薛剑 , 等. 胸腺五肽辅助治疗耐多药肺结核的临床效果及对免疫系统的影响. 临床肺科杂志, 2016,21(7):1279-1282. |
[28] | 张春莉, 刘照惠, 王妍 , 等. 胸腺五肽固相合成及免疫增强作用的研究. 中国生物制品学杂志, 2003,16(2):87-89. |
[29] | 赵玉红 . 注射用胸腺五肽的质量研究. 长春: 吉林大学, 2007. |
[30] | 左朋飞, 韩香, 刘璐 . 胸腺五肽的合成及临床应用进展. 天津药学, 2008,20(1):53-57. |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||